CliffBio
small molecule

DEFENCATH

HEPARIN SODIUM; TAUROLIDINE

Loss of exclusivityApril 2042latest FDA-listed patent expiry
CompanyCorMedix →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEFENCATH
Active ingredientHEPARIN SODIUM; TAUROLIDINE
Strength5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML)
Dosage formSOLUTION
RouteN/A
ModalitySmall molecule
FDA approvalNovember 2023
Marketing statusRX

Listed patents

PatentExpiresType
11738120April 2042substance, product
7696182May 2026substance, product

Regulatory exclusivity

CodeExpires
GAINNovember 2033
NCENovember 2028

More from CorMedix

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.